Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Beta Bionics, Inc. - Common Stock (NQ:BBNX)

12.83 -1.44 (-10.09%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,004,577
Open 13.99
Bid (Size) 11.63 (400)
Ask (Size) 13.27 (100)
Prev. Close 14.27
Today's Range 12.79 - 14.28
52wk Range 8.800 - 32.71
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Beta Bionics Q2 Earnings Call Highlights ↗
Beta Bionics (NASDAQ:BBNX) reported second-quarter 2026 net sales of $32 million, up approximately 38% from a year earlier, as new patient starts and recurring pharmacy-channel supply revenue supported... 
Via MarketBeat
Topics Earnings
Beta Bionics (NASDAQ:BBNX) Q2: EPS Beat and Margin Progress Lift Shares 3% After Hours ↗
Via Chartmill

Performance

YTD
-56.1%
-56.1%
1 Month
-18.1%
-18.1%
3 Month
+25.8%
+25.8%
6 Month
-13.3%
-13.3%
1 Year
-23.4%
-23.4%

More News

Read More
News headline image
Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance
From Beta Bionics, Inc.
Via GlobeNewswire
News headline image
Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026
From Beta Bionics, Inc.
Via GlobeNewswire
News headline image
Johnson Fistel Continues Investigation of Beta Bionics, Inc. (BBNX)
From Johnson Fistel, PLLP
Via Business Wire
Beta Bionics Inc (NASDAQ:BBNX) Beats Q1 2026 Estimates and Raises Full-Year Guidance ↗
Via Chartmill
News headline image
Beta Bionics Investors Suffer Significant Losses After Company Reports Slower New Patient Start Growth; Contact Johnson Fistel
From Johnson Fistel, PLLP
Via Business Wire
News headline image
Beta Bionics First in Automated Insulin Delivery to Publish Near Real-Time Real-World Data on a Public Website
From Beta Bionics, Inc.
Via GlobeNewswire
News headline image
Robbins LLP is Investigating Allegations that the Officers and Directors of Beta Bionics, Inc. (BBNX) Violated Securities Laws and Breached Fiduciary Duties to Shareholders
From Robbins LLP
Via Business Wire
News headline image
Beta Bionics Updates Commercialization Timeline Expectations for Mint™, its Patch Pump in Development
From Beta Bionics, Inc.
Via GlobeNewswire
News headline image
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Beta Bionics Touts Pharmacy Push, iLet Momentum and 2027 Mint Patch Pump Plans ↗
Via MarketBeat
News headline image
Beta Bionics to Present at the Bank of America Securities Health Care Conference
From Beta Bionics, Inc.
Via GlobeNewswire
News headline image
Beta Bionics BBNX Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
From Beta Bionics, Inc.
Via GlobeNewswire
News headline image
Beta Bionics Introduces Bionic Insights™ in Bionic Reports — Transforming How Clinicians Understand and Optimize Diabetes Care
From Beta Bionics, Inc.
Via GlobeNewswire
News headline image
Beta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026
From Beta Bionics, Inc.
Via GlobeNewswire
News headline image
BBNX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
ONGOING INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Continues Investigation of Potential Securities Claims Against Beta Bionics (NASDAQ: BBNX)
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
BBNX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Launches Investigation into Beta Bionics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
BBNX INVESTOR NOTICE: Faruqi & Faruqi, LLP Launches Investigation into Beta Bionics
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
BBNX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
From Faruqi & Faruqi LLP
Via GlobeNewswire

Frequently Asked Questions

Is Beta Bionics, Inc. - Common Stock publicly traded?
Yes, Beta Bionics, Inc. - Common Stock is publicly traded.
What exchange does Beta Bionics, Inc. - Common Stock trade on?
Beta Bionics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Beta Bionics, Inc. - Common Stock?
The ticker symbol for Beta Bionics, Inc. - Common Stock is BBNX on the Nasdaq Stock Market
What is the current price of Beta Bionics, Inc. - Common Stock?
The current price of Beta Bionics, Inc. - Common Stock is 12.83
When was Beta Bionics, Inc. - Common Stock last traded?
The last trade of Beta Bionics, Inc. - Common Stock was at 07/31/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.